166 related articles for article (PubMed ID: 19758279)
1. Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome.
Mihm U; Hofmann WP; Welsch C; Polta A; Lengauer T; Zeuzem S; Sarrazin C; Herrmann E
J Viral Hepat; 2010 Mar; 17(3):217-21. PubMed ID: 19758279
[TBL] [Abstract][Full Text] [Related]
2. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy.
Hofmann WP; Polta A; Herrmann E; Mihm U; Kronenberger B; Sonntag T; Lohmann V; Schönberger B; Zeuzem S; Sarrazin C
Gastroenterology; 2007 Mar; 132(3):921-30. PubMed ID: 17383421
[TBL] [Abstract][Full Text] [Related]
3. Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
Arataki K; Kumada H; Toyota K; Ohishi W; Takahashi S; Tazuma S; Chayama K
Intervirology; 2006; 49(6):352-61. PubMed ID: 16926548
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C.
Mihm U; Ackermann O; Welsch C; Herrmann E; Hofmann WP; Grigorian N; Welker MW; Lengauer T; Zeuzem S; Sarrazin C
J Hepatol; 2009 Jan; 50(1):49-58. PubMed ID: 19022516
[TBL] [Abstract][Full Text] [Related]
5. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
[TBL] [Abstract][Full Text] [Related]
6. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I
J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646
[TBL] [Abstract][Full Text] [Related]
7. Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions.
Quiles-Pérez R; Muñoz-de-Rueda P; Maldonado AM; Martín-Álvarez A; Quer J; Salmerón J
J Med Virol; 2014 Nov; 86(11):1886-97. PubMed ID: 25091333
[TBL] [Abstract][Full Text] [Related]
8. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
[TBL] [Abstract][Full Text] [Related]
9. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
[TBL] [Abstract][Full Text] [Related]
10. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA
J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227
[TBL] [Abstract][Full Text] [Related]
11. Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.
Chary A; Winters MA; Kottilil S; Murphy AA; Polis MA; Holodniy M
J Infect Dis; 2010 Sep; 202(6):889-93. PubMed ID: 20677940
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of hepatitis C virus RNA to the antiviral enzyme ribonuclease L is determined by a subset of efficient cleavage sites.
Han JQ; Wroblewski G; Xu Z; Silverman RH; Barton DJ
J Interferon Cytokine Res; 2004 Nov; 24(11):664-76. PubMed ID: 15684820
[TBL] [Abstract][Full Text] [Related]
13. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA.
Kanda T; Yokosuka O; Imazeki F; Tanaka M; Shino Y; Shimada H; Tomonaga T; Nomura F; Nagao K; Ochiai T; Saisho H
J Viral Hepat; 2004 Nov; 11(6):479-87. PubMed ID: 15500548
[TBL] [Abstract][Full Text] [Related]
15. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S
J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079
[TBL] [Abstract][Full Text] [Related]
16. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L.
Washenberger CL; Han JQ; Kechris KJ; Jha BK; Silverman RH; Barton DJ
Virus Res; 2007 Dec; 130(1-2):85-95. PubMed ID: 17604869
[TBL] [Abstract][Full Text] [Related]
18. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.
Sugihara K; Orito E; Tanaka Y; Kato T; Lau JY; Ohno T; Hayashi K; Ogino M; Hirashima N; Sakakibara K; Mizuno Y; Kato H; Suzuki S; Ueda R; Mizokami M
Intervirology; 2006; 49(6):319-26. PubMed ID: 16926544
[TBL] [Abstract][Full Text] [Related]
19. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.
Caetano J; Martinho A; Paiva A; Pais B; Valente C; Luxo C
J Virol; 2008 Aug; 82(15):7567-77. PubMed ID: 18480446
[TBL] [Abstract][Full Text] [Related]
20. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.
Querenghi F; Yu Q; Billaud G; Maertens G; Trépo C; Zoulim F
J Viral Hepat; 2001 Mar; 8(2):120-31. PubMed ID: 11264732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
